Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 6/20 | 0.52 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16468502 | 1.00 | GHSR (0.52) | GHSRFKBP1APOLBALDH1A1TP53 | |
| SCHEMBL15543487 | 0.91 | SMN1; SMN2 (0.48) | GHSRFKBP1APOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL15543486 | 0.91 | SMN1; SMN2 (0.48) | GHSRFKBP1APOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL16468189 | 0.89 | MDH1 (0.47) | GHSRFKBP1AALDH1A1USP2TSHR | |
| SCHEMBL15543280 | 0.89 | MDH1 (0.47) | GHSRFKBP1AALDH1A1USP2TSHR | |
| SCHEMBL16468384 | 0.87 | NPC1 (0.47) | GHSRFKBP1APOLBALDH1A1TP53 | |
| SCHEMBL15542733 | 0.87 | NPC1 (0.47) | GHSRFKBP1APOLBALDH1A1TP53 | |
| SCHEMBL15543714 | 0.85 | FKBP1A (0.43) | GHSRFKBP1APOLBALDH1A1TP53 | |
| SCHEMBL15543715 | 0.85 | FKBP1A (0.43) | GHSRFKBP1APOLBALDH1A1TP53 | |
| SCHEMBL4727917 | 0.81 | PLA2G4B (0.53) | POLBALDH1A1SMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150051144-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES | CADILA HEALTHCARE LTD (IN) | 2015-02-19 | — | — | US | claimed |
| US-20150051144-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES | CADILA HEALTHCARE LTD (IN) | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051144-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES | PCSK9, HMGCR, CETP | GHSR 1040/4885FKBP1A 1033/4885POLB 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.